v3.25.2
Reportable segment disclosure - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses $ 33,693 $ 25,374 $ 55,176 $ 46,777
Sales & Marketing 419 986 681 1,744
General & Administrative 8,463 8,643 14,089 16,447
Total 42,575 35,003 69,946 64,968
Viaskin Peanut Segment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Sales & Marketing 419 986 681 1,744
General & Administrative 8,463 8,643 14,089 16,447
Total 42,575 35,003 69,946 64,968
Viaskin Peanut Segment | Clinical studies        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses 16,258 13,056 23,060 21,229
Viaskin Peanut Segment | BLA & Regulatory        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses 2,298 1,610 3,683 3,090
Viaskin Peanut Segment | Medical Affairs & Other Medical        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses 2,009 1,626 3,967 4,290
Viaskin Peanut Segment | Research & Innovation        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses 342 575 1,086 765
Viaskin Peanut Segment | Manufacturing & Supply and Quality        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and Development expenses $ 12,786 $ 8,507 $ 23,380 $ 17,403